Sven Dethlefs (Ph.D) became Executive Vice President, North America Commercial in August 2021, leading all commercial activities of Teva USA and Teva Canada’s Generic and Specialty businesses.
Headquartered in Parsippany, NJ, Teva USA’s generic medicines saved the US healthcare system $28.8B in 2020 alone, and in the US, 10 prescriptions are filled with a Teva product every second. Teva USA maintains leadership positions with broad generic and specialty portfolios across varying therapeutic conditions, including movement disorders, mental health and respiratory. Teva Canada, headquartered in Toronto, has provided affordable healthcare solutions to Canadians for over 50 years, with currently more than 179,000 prescriptions filled each day.
Sven Dethlefs has been part of Teva’s Executive Management team since 2017, where he served as Executive Vice President, Global Marketing and Portfolio, assuming responsibility for International Markets, Commercial in 2021. He also held leadership roles in Teva’s Global Specialty business, Commercial European business and Global Operations (TGO). Sven has played an integral role in optimizing Teva's vast global portfolio, in developing the R&D pipeline strategy, and leading global marketing teams.
Sven joined Teva as General Manager, Teva Germany in 2008. Prior to joining Teva, he served for over eleven years as a partner at McKinsey & Company.
Sven received his Ph.D. in biochemistry from the FU Berlin/Pasteur Institute Paris.
What is Sven Dethlefs' net worth?
The estimated net worth of Sven Dethlefs is at least $2.90 million as of March 6th, 2023. Dr. Dethlefs owns 223,447 shares of Teva Pharmaceutical Industries stock worth more than $2,895,873 as of April 19th. This net worth approximation does not reflect any other assets that Dr. Dethlefs may own. Learn More about Sven Dethlefs' net worth.
How do I contact Sven Dethlefs?
Has Sven Dethlefs been buying or selling shares of Teva Pharmaceutical Industries?
Sven Dethlefs has not been actively trading shares of Teva Pharmaceutical Industries during the past quarter. Most recently, Sven Dethlefs sold 19,355 shares of the business's stock in a transaction on Monday, March 6th. The shares were sold at an average price of $9.93, for a transaction totalling $192,195.15. Following the completion of the sale, the executive vice president now directly owns 223,447 shares of the company's stock, valued at $2,218,828.71. Learn More on Sven Dethlefs' trading history.
Who are Teva Pharmaceutical Industries' active insiders?
Teva Pharmaceutical Industries' insider roster includes Rosemary Crane (Director), Richard Daniell (VP), Sven Dethlefs (EVP), Eric Drape (VP), Hafrun Fridriksdottir (VP), Eric Hughes (insider), Eliyahu Kalif (CFO), Mark Sabag (Insider), Eli Shani (EVP), David Stark (VP), and Amir Weiss (CAO). Learn More on Teva Pharmaceutical Industries' active insiders.
Are insiders buying or selling shares of Teva Pharmaceutical Industries?
During the last twelve months, insiders at the sold shares 9 times. They sold a total of 480,586 shares worth more than $5,931,942.06. The most recent insider tranaction occured on March, 5th when EVP Mark Sabag sold 100,000 shares worth more than $1,352,000.00. Insiders at Teva Pharmaceutical Industries own 0.6% of the company.
Learn More about insider trades at Teva Pharmaceutical Industries. Information on this page was last updated on 3/5/2024.
